EVERYTHING ABOUT (+)-JQ-1 ANTICANCER ACTIVITY

Semaglutide, a glucagon like peptide-1 (GLP-one) receptor agonist, is obtainable as monotherapy in equally subcutaneous as well as oral dosage type (initially accepted oral GLP-1 receptor agonist). It's been authorised as a 2nd line therapy selection for improved glycaemic Regulate in type two diabetes and currently below scrutiny for anti-obesity